Adverum Biotechnologies Inc (ADVM) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Adverum Biotechnologies Inc (ADVM) has a cash flow conversion efficiency ratio of 0.505x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-28.11 Million) by net assets ($-55.65 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see ADVM market cap for the company's overall valuation and market capitalisation.
Adverum Biotechnologies Inc - Cash Flow Conversion Efficiency Trend (2012–2024)
This chart illustrates how Adverum Biotechnologies Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Adverum Biotechnologies Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Adverum Biotechnologies Inc ranked by their cash flow conversion efficiency. See Adverum Biotechnologies Inc (ADVM) debt coverage ratio to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Virco Manufacturing Corporation
NASDAQ:VIRC
|
-0.091x |
|
Arihant Capital Markets Limited
NSE:ARIHANTCAP
|
-0.250x |
|
1-800 FLOWERS.COM Inc
NASDAQ:FLWS
|
-0.665x |
|
Leo Systems
TWO:5410
|
0.402x |
|
UNITRAD
KLSE:0247
|
-0.045x |
|
Accel Solutions Group Ltd
TA:ACCL
|
-0.026x |
|
Buriram Sugar Public Company Limited
BK:BRR
|
0.107x |
|
Laiqon AG
XETRA:LQAG
|
0.037x |
Annual Cash Flow Conversion Efficiency for Adverum Biotechnologies Inc (2012–2024)
The table below shows the annual cash flow conversion efficiency of Adverum Biotechnologies Inc from 2012 to 2024. View ADVM stock price and chart for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $70.71 Million | $-92.46 Million | -1.308x | +3.31% |
| 2023-12-31 | $67.22 Million | $-90.90 Million | -1.352x | -127.09% |
| 2022-12-31 | $181.52 Million | $-108.09 Million | -0.595x | -74.61% |
| 2021-12-31 | $316.19 Million | $-107.83 Million | -0.341x | -86.82% |
| 2020-12-31 | $434.35 Million | $-79.29 Million | -0.183x | +35.04% |
| 2019-12-31 | $174.96 Million | $-49.17 Million | -0.281x | -4.77% |
| 2018-12-31 | $201.17 Million | $-53.96 Million | -0.268x | -8.69% |
| 2017-12-31 | $184.03 Million | $-45.42 Million | -0.247x | -38.70% |
| 2016-12-31 | $215.60 Million | $-38.37 Million | -0.178x | -27.20% |
| 2015-12-31 | $252.59 Million | $-35.34 Million | -0.140x | -270.27% |
| 2014-12-31 | $149.48 Million | $-5.65 Million | -0.038x | -100.38% |
| 2013-12-31 | $-218.00K | $-2.17 Million | 9.977x | +685.09% |
| 2012-12-31 | $-997.00K | $-1.27 Million | 1.271x | -- |
About Adverum Biotechnologies Inc
Adverum Biotechnologies, Inc., a clinical-stage company, develops gene therapy product candidates to treat ocular diseases. Its lead product candidate is ixoberogene soroparvovec Ixo-vec, a single intravitreal injection gene therapy candidate used for the treatment of patients with wet age-related macular degeneration and diabetic macular edema which is in phase 2 clinical trials. The company is … Read more